A detailed history of Reuter James Wealth Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Reuter James Wealth Management, LLC holds 1,699 shares of VRTX stock, worth $765,178. This represents 0.15% of its overall portfolio holdings.

Number of Shares
1,699
Previous 1,669 1.8%
Holding current value
$765,178
Previous $782,000 1.02%
% of portfolio
0.15%
Previous 0.58%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$460.0 - $505.78 $13,800 - $15,173
30 Added 1.8%
1,699 $790,000
Q2 2024

Aug 01, 2024

SELL
$392.81 - $485.53 $63,242 - $78,170
-161 Reduced 8.8%
1,669 $782,000
Q1 2024

May 06, 2024

SELL
$407.69 - $446.08 $30,576 - $33,456
-75 Reduced 3.94%
1,830 $764,000
Q4 2023

Apr 08, 2024

SELL
$343.0 - $410.68 $46,648 - $55,852
-136 Reduced 6.66%
1,905 $775,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $18,938 - $20,297
-56 Reduced 2.67%
2,041 $709,000
Q2 2023

Aug 07, 2023

SELL
$314.42 - $351.91 $10,061 - $11,261
-32 Reduced 1.5%
2,097 $737,000
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $7,647 - $8,723
-27 Reduced 1.25%
2,129 $670,000
Q4 2022

Feb 06, 2023

SELL
$285.76 - $321.48 $20,288 - $22,825
-71 Reduced 3.19%
2,156 $622,000
Q3 2022

Nov 04, 2022

SELL
$273.83 - $305.53 $163,202 - $182,095
-596 Reduced 21.11%
2,227 $645,000
Q2 2022

Aug 09, 2022

SELL
$234.96 - $292.55 $180,684 - $224,970
-769 Reduced 21.41%
2,823 $795,000
Q1 2022

Apr 14, 2022

SELL
$221.42 - $260.97 $78,382 - $92,383
-354 Reduced 8.97%
3,592 $937,000
Q4 2021

Jan 25, 2022

BUY
$177.01 - $223.45 $698,481 - $881,733
3,946 New
3,946 $867,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Reuter James Wealth Management, LLC Portfolio

Follow Reuter James Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reuter James Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reuter James Wealth Management, LLC with notifications on news.